Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D31-palmitate is a perdeuterated form of palmitic acid used as a metabolic tracer in deuterium metabolic imaging (DMI). It contains 31 deuterium atoms replacing the hydrogen atoms on the palmitate carbon chain, allowing for the non-invasive monitoring of lipid metabolism via magnetic resonance spectroscopy or imaging. In oncological research, specifically glioblastoma (GBM), D31-palmitate is used to investigate the uptake and oxidation of exogenous fatty acids. Research conducted at Washington University in St. Louis has utilized D31-palmitate to differentiate between de novo lipogenesis (often tracked with deuterium oxide) and the utilization of dietary or systemic lipids within the tumor microenvironment. Unlike radioactive tracers, D31-palmitate utilizes stable isotopes, making it a safer alternative for dynamic interrogation of fatty acid distribution in both neoplastic and normal tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D31-palmitate.